Hair growth peptides: which pathways are being researched

Research context (RUO): The peptides on this page are studied in models of the hair follicle. Everything below describes published laboratory and animal research. Peplife supplies these substances solely for in-vitro laboratory research (Research Use Only), not for human or animal use, and makes no claims about effects in humans.

Hair growth peptides: which pathways are being researched

The term hair growth peptides covers a handful of short peptides that, in preclinical research, each engage the hair follicle through a route of their own. Some target the signalling pathway that determines when a follicle starts a new growth phase, others the blood supply or the build-up of the surrounding matrix. What they share is a research field, not a mechanism of action. This pillar page lines up the four peptides that come up most often in this field and describes, per substance, what evidence exists and how extensive that evidence is.

The biology: hair cycle, dermal papilla and Wnt signalling

A hair follicle continuously runs through a cycle of growth (anagen), regression (catagen) and rest (telogen). Which phase is active is largely determined by signals from the dermal papilla, a small cluster of connective tissue cells at the base of the follicle. The Wnt-beta-catenin pathway is the key switch here: once it becomes active, a new growth phase begins. Almost all peptide research around hair growth engages somewhere in this chain, or in the blood flow and matrix build-up that make a growth phase possible.

PTD-DBM: blocking CXXC5 to release Wnt again

PTD-DBM has the most specific point of engagement in this group. The protein CXXC5 inhibits the Wnt pathway by binding to Dishevelled. PTD-DBM mimics that binding domain and competes CXXC5 away, taking the brake off. In the work of Lee and colleagues from 2017, topical application of this competing peptide in mouse models led to reactivation of the hair cycle, with the strongest effect when it was combined with valproic acid. The research is narrow but mechanistically well substantiated. The pillar page on PTD-DBM research goes deeper into the CXXC5 pathway.

AHK-Cu: copper peptide focused on the dermal papilla

AHK-Cu is a tripeptide (alanyl-histidyl-lysine) that binds copper. In-vitro studies with dermal papilla cells looked at cell proliferation and at the expression of growth factors associated with the anagen phase, including VEGF. The evidence is limited to a small number of cell studies and the dose response turns out to be bell-shaped: outside a narrow concentration range the effect disappears. That makes AHK-Cu interesting as a research model, but the evidence is considerably thinner than for its better-known cousin.

GHK-Cu: copper peptide with a broad regenerative profile

GHK-Cu (glycyl-histidyl-lysine with copper) is by far the best documented copper peptide. The research focuses mainly on skin, collagen and wound healing, with gene expression data mapping hundreds of genes at once. Hair follicle research is a smaller sub-area within that. Anyone wanting to compare the two copper peptides directly will find that in the pillar page Compare GHK-Cu and AHK-Cu.

Thymosin beta-4 and TB-500: blood flow around the follicle

Thymosin beta-4 is an endogenous protein that binds actin and is involved in cell migration and the formation of new blood vessels. In mouse models it has been described as influencing follicle development, probably indirectly via angiogenesis and migration of follicle stem cells. TB-500 is its synthetic core fragment. Research into this route sits further from the hair cycle than the work on PTD-DBM, but it does touch on the same preconditions. See the pillar page TB-500 research for the full context.

The four peptides side by side

How this research relates to existing hair growth agents

In the published animal models, peptides are regularly placed alongside a known reference substance, because a comparison arm is needed to interpret an effect. That does not make the peptides an alternative: the studies are preclinical, mostly in mice, and none of these substances is registered as a hair growth agent with the EMA, NVWA or FDA. The comparison in those publications says something about the strength of a signal in a model, not about use in humans.

Topical versus systemic in research models

A practical distinction that is often missed: in the published research, PTD-DBM and the copper peptides were almost always applied locally to the skin, while TB-500 was given systemically in animal models. That difference determines which concentration actually reaches the follicle and makes direct comparison of dosages meaningless. Anyone laying protocols side by side therefore has to align the route of administration first, before any numbers mean anything.

Hair growth peptides in laboratory research: handling and dissolving

All four are supplied as freeze-dried powder. Copper peptides are sensitive to light and to pH shifts: the copper-histidine bond is the reason the solution turns blue, and that colour is itself a rough indicator that the complex is intact. After reconstitution, PTD-DBM and TB-500 should be stored cold and dark, and they tolerate repeated freezing poorly. The reconstitution guide sets out the calculation steps and the practicalities of preparation and storage.

Quality & purity

With copper peptides, what counts alongside peptide purity is whether the copper complex has actually formed; with PTD-DBM it is a longer chain in which synthesis errors accumulate more easily. Every relevant batch is independently HPLC tested by an external laboratory and the certificate of analysis is publicly verifiable per batch, so the research material demonstrably matches the specified peptide. In the pillar page why we rejected a batch you can read how that process works in practice.

Frequently asked questions about hair growth peptides

Which hair growth peptide has the strongest research record?
Mechanistically, PTD-DBM is the most sharply substantiated, because the CXXC5 target and the pathway around it have been mapped explicitly. In total volume of publications GHK-Cu is by far the largest, but that research is only partly about the hair follicle.

What is the difference between AHK-Cu and GHK-Cu?
Both are copper-binding tripeptides, but with a different first amino acid. GHK-Cu has been studied broadly on skin and collagen, AHK-Cu almost exclusively on dermal papilla cells.

Do these peptides work complementarily?
They engage at different points, so combination research is logical in theory. Published studies that combine these peptides with each other are however scarce; the combinations that have been studied pair PTD-DBM with other classes of substances.

Are these substances approved against hair loss?
No. None of these peptides is registered as a medicine or cosmetic active ingredient against hair loss with the EMA, NVWA or FDA. They are supplied solely for laboratory research.

Why is the dose response of copper peptides bell-shaped?
At higher concentrations the effect reverses, probably because free copper itself causes oxidative stress. In cell studies that means: outside a narrow range the measured effect disappears or turns around.

Read more & research at Peplife

• Research PTD-DBM at Peplife
• Research AHK-Cu at Peplife
• Research GHK-Cu at Peplife
• Research TB-500 at Peplife
• View all skin peptides
• PTD-DBM: research into the CXXC5 pathway
• Compare GHK-Cu and AHK-Cu
• TB-500: research into the thymosin fragment
• Skin and tanning peptides: the overview

Sources: Lee et al., J Invest Dermatol 2017 — Targeting of CXXC5 by a Competing Peptide · Pickart & Margolina, GHK-Cu and skin regeneration, IJMS 2018 · PubChem — AHK-Cu copper peptide · Thymosin beta-4, cell migration and repair (PubMed)

Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.